Skip to main content

Table 5 The baseline characteristics of training and validation set

From: Risk factors for metastasis and poor prognosis of Ewing sarcoma: a population based study

CharacteristicAll patients (N = 1160)
Number (%)
Traning set (N = 570, 49.1%)
Number (%)
Validation set (N = 590, 50.9%)
Number (%)
p value
Age (years)  0.349
 ≤ 10242 (20.9%)117 (20.5%)125 (21.2%) 
 11–20571 (49.2%)288 (50.5%)283 (48.0%) 
 21–30206 (17.8%)105 (18.4%)101 (17.1%) 
 31–49101 (8.7%)46 (8.1%)55 (9.3%) 
 ≥ 5040 (3.4%)14 (2.5%)26 (4.4%) 
Gender   0.084
 Male733 (63.2%)346 (60.7%)387 (65.6%) 
 Female427 (36.8%)224 (39.3%)203 (34.4%) 
Race   0.727
 White1041 (89.7%)511 (89.6%)530 (89.8%) 
 Black30 (2.6%)13 (2.3%)17 (2.9%) 
 Other89 (7.7%)46 (8.1%)43 (7.3%) 
Primary site   0.384
 Limb519 (44.7%)254 (44.6%)265 (44.9%) 
 Cranial66 (5.7%)32 (5.6%)34 (5.8%) 
 Spine88 (7.6%)37 (6.5%)51 (8.6%) 
 Thoracic173 (14.9%)95 (16.7%)78 (13.2%) 
 Pelvic314 (27.1%)152 (26.7%)162 (27.5%) 
Tumor size (cm)   0.296
 < 5221 (19.1%)119 (20.9%)102 (17.3%) 
 5–8371 (32.0%)179 (31.4%)192 (32.5%) 
 > 8568 (49.0%)272 (47.7%)296 (50.2%) 
Tumor extent   0.985
 Localized311 (26.8%)153 (26.8%)158 (26.8%) 
 Regional533 (45.9%)263 (46.1%)270 (45.8%) 
 Metastatic316 (27.2%)154 (27.0%)162 (27.5%) 
Cancer-directed surgery   0.651
 No390 (33.6%)188 (33.0%)202 (34.2%) 
 Yes770 (66.4%)382 (67.0%)388 (65.8%) 
Radiation   0.636
 No584 (50.3%)291 (51.1%)293 (49.7%) 
 Yes576 (49.7%)279 (48.9%)297 (50.3%) 
Chemotherapy   0.032*
 No40 (3.4%)13 (2.3%)27 (4.6%) 
 Yes1120 (96.6%)557 (97.7%)563 (95.4%) 
  1. p value < 0.05*